Evidence map›Paper›PMID 32681939›Full record

ArticleNeuroscience and biobehavioral reviews2020

Lost in translation: At the crossroads of face validity and translational utility of behavioral assays in animal models for the development of therapeutics.

J L Silverman, J Nithianantharajah, A Der-Avakian, J W Young, S J Sukoff Rizzo

Abstract read
In one paragraph

Article in Neuroscience and biobehavioral reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Reverse Translation.Perspectives on behavior science · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Perspectives on Cognitive Phenotypes and Models of Vascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2022
    Review
  18. Review
  19. Probabilistic Reinforcement Learning and Anhedonia.Current topics in behavioral neurosciences · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

J L SilvermanUniversity of California, Davis, MIND Institute, School of Medicine, Department of Psychiatry and Behavioral Sciences, Sacramento, CA, USA.
J NithianantharajahThe Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.
A Der-AvakianDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
J W YoungDepartment of Psychiatry, University of California San Diego, La Jolla, CA, USA.
S J Sukoff RizzoUniversity of Pittsburgh School of Medicine, Department of Medicine, Pittsburgh, PA, USA. Electronic address: rizzos@pitt.edu.

Funding

The IU/JAX Alzheimer's Disease Precision Models Center: Rat F344U54AG054345 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI Gareth R Howell · 2016 to 2026
$95.6M
TREAT AD Structural Biology CoreU54AG065187 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2019 to 2026
$69.7M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
Research Project: Pathologic Significance of Maternal AutoantibodiesP50HD103526 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JUDY A. VAN DE WATER · 2020 to 2026
$9.7M
Rodent Behavior CoreU54HD079125 · NICHD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBEDUTO, LEONARD J. · 2013 to 2019
$8.5M
Phenotypic Characterization of Novel Models of Dup15q SyndromeR01NS097808 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SILVERMAN, JILL LYNN · 2017 to 2021
$1.7M
Preclinical neurophysiological and behavioral assays of motivation and effortR01MH121352 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DER-AVAKIAN, ANDRE · 2019 to 2022
$1.6M
Neurophysiological biomarkers of behavioral dimensions from cross-species paradigmsUH3MH109168 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI YOUNG, JARED WILLIAM · 2018 to 2019
$1.0M
Improving Preclinical Translation in Alzheimer's Disease ResearchR13AG060708 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Stacey J Rizzo · 2018 to 2026
$394k
NIA NIH HHS P30 AG010129NIA NIH HHS R13 AG060708NIA NIH HHS U54 AG054345NIA NIH HHS U54 AG065187NICHD NIH HHS P50 HD103526NICHD NIH HHS U54 HD079125NIMH NIH HHS R01 MH121352NIMH NIH HHS UH3 MH109168NINDS NIH HHS R01 NS097808
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Translational Research, BiomedicalAnimalsDisease Models, AnimalModels, AnimalReproducibility of Results

Identifiers

PMID32681939
PMCPMC7773218

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.